financetom
Business
financetom
/
Business
/
TCS Q3 net profit jumps 24% YoY to Rs 8,105 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TCS Q3 net profit jumps 24% YoY to Rs 8,105 crore
Jan 10, 2019 8:04 AM

India’s largest IT services firm, Tata Consultancy Services (TCS), on Thursday posted 24 percent year-on-year (YoY) rise in profit at Rs 8,105 crore for the third quarter.

The Mumbai-based information technology (IT) outsourcing company had posted a net profit of Rs 6,531 crore in the corresponding period last fiscal.

Its income from operations during the quarter under review stood at Rs 37,338 crore, up 20.8 percent from Rs 30,904 crore crore in the year-ago period, the company said in a BSE filing.

Operating margin for the quarter stood at 25.6 percent, an expansion of 0.4 percent YoY.

Digital accounted for 30.1 percent of the revenues, registering year-on-year growth of 52.7 percent.

The company has declared a dividend of Rs 4 per share.

In Q3, the company added 6,827 employees on a net basis. Total employee strength at the end of Q3 stood at 417,929 on a consolidated basis. The percentage of women in the workforce rose further to 35.8 percent, while the total number of nationalities represented grew to 151, the company said.

As on December 31,2018, TCS has applied for 4,354 patents, including 169 applied during the quarter and has been granted 855 patents.

Commenting on the Q3 performance, Rajesh Gopinathan, chief executive officer and managing director, said, "We are wrapping up 2018 with a strong revenue growth of 12.1 percent in the December quarter, which is the highest in 14 quarters, with continued growth acceleration in key verticals and across all geographies."

"The strong client metrics, industry leading growth in digital services, a very strong order book and deal pipeline are all validations that customers recognize our differentiated capabilities and are picking us for their growth and transformation programs," he added.

The company's chief financial officer V Ramakrishnan said despite headwinds from the rupee volatility against various currencies, and the higher cost of doing business in some major markets, TCS' operating margins have been resilient.

"We remain focused on driving rigour in our operations, generating strong cash flows and steering profitability back to our preferred range, while continuing to invest strongly for future growth," he added.

First Published:Jan 10, 2019 5:04 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EnLink Midstream to Launch Senior Notes Offering
EnLink Midstream to Launch Senior Notes Offering
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- EnLink Midstream ( ENLC ) said Monday that it plans to launch an offering of senior notes. The midstream energy company said it plans to use the net proceeds to repay borrowings under its revolving credit facility, as well as an accounts receivable securitization facility. EnLink said the offering will be fully guaranteed...
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that Anktiva is now available for patients under both commercial and government insurance plans in the US. The US Food and Drug Administration approved Anktiva, the company's immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, in April. Additionally, ImmunityBio ( IBRX ) has started the filing...
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Aug 12, 2024
09:26 AM EDT, 08/12/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) said Monday the US Food and Drug Administration has given rare pediatric disease designation to its drug candidate WVE-N531 to treat boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping. The drug is being assessed in a trial that enrolled 11 boys with the...
What's Going On With Bitcoin Mining Stock Marathon Digital Monday?
What's Going On With Bitcoin Mining Stock Marathon Digital Monday?
Aug 12, 2024
Marathon Digital Holdings Inc ( MARA ) shares are trading lower. The company on Monday announced a proposed private offering of convertible senior notes. What Happened: Bitcoin (CRYPTO: BTC) mining company Marathon Digital ( MARA ) said it intends to offer $250 million worth of convertible senior notes due 2031 in a private offering to institutional buyers. The company expects...
Copyright 2023-2026 - www.financetom.com All Rights Reserved